Contribute Try STAT+ Today

Rise and shine, folks, another busy day is on the way. We can tell because our short person is, once again, hunched over a laptop and our official mascot has an early play date on the campus grounds with another pup from the hood. This leaves us to fire up the trusty coffee kettle and tackle our fluctuating to-do list. On that note, here are a few items of interest to help you on your own journey today, which we hope is productive and meaningful. Meanwhile, stay in touch and stay safe — wear a mask. …

Regeneron Pharmaceuticals (REGN) reported that its monoclonal antibody cocktail prevented Covid-19 in a clinical trial, STAT notes. The news, issued via a press release, mirrored similar news last week from Eli Lilly (LLY) that its monoclonal antibody prevented symptomatic Covid-19 infections in nursing homes. The results represent the first 400 volunteers from the study, which is being run by the National Institute of Allergy and Infectious Diseases, and is continuing to enroll patients. The volunteers were at high risk of infection because they lived in the same household as a Covid-19 patient.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.